1800-272-662
Shopping Cart 0
countryflagAU
Login

Revelation Biosciences Inc

Healthcare US REVB

1.34USD
0.06(4.69%)

Last update at 2026-03-10T20:21:00Z

Day Range

1.261.36
LowHigh

52 Week Range

1.7135.40
LowHigh

Fundamentals

  • Previous Close 1.28
  • Market Cap2.82M
  • Volume95179
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.63162M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 90.91M
  • Diluted EPS TTM-48.51

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -10.82955M -11.98684M -0.13641M 43.30M 37.05M
Minority interest - - - - -
Net income -10.79459M -11.98684M -0.13641M 31.70M 27.63M
Selling general administrative 5.49M 5.04M 0.15M 36.34M 33.98M
Selling and marketing expenses - - - - -
Gross profit - - - 90.91M 80.98M
Reconciled depreciation 0.03M 0.02M - - -
Ebit -10.86451M -11.95049M -3.79582M - 0.00000M
Ebitda -10.83946M -11.93370M -0.14549M - -
Depreciation and amortization 0.03M 0.02M - - -
Non operating income net other - - - - -
Operating income -10.86451M -11.95049M -0.14549M 45.18M 38.89M
Other operating expenses 10.86M 11.95M 0.15M 4.29M 4.07M
Interest expense 0.03M 0.04M 0.00000M 0.00000M 0.00000M
Tax provision - - - 11.60M 9.43M
Interest income - - - 129.34M 106.97M
Net interest income - - - 92.87M 82.84M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.03496M 0.04M - 11.60M 9.43M
Total revenue 0.00000M 0.00000M - 95.81M 85.11M
Total operating expenses 10.86M 11.95M 0.15M 45.73M 42.09M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.03M -0.03635M 0.00908M -1.88200M -1.84200M
Discontinued operations - - - - -
Net income from continuing ops -10.82955M -11.98684M - 31.70M 27.63M
Net income applicable to common shares - -2.13063M -3.79569M 31.70M 27.63M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 12.21M 5.50M 2.04M 4.62M 2851.18M
Intangible assets - - - - 2.92M
Earning assets - - - - -
Other current assets 0.08M 0.07M 0.64M 0.13M 7.67M
Total liab 5.56M 4.45M 2.14M 1.21M 2547.55M
Total stockholder equity 6.65M 1.05M -0.09947M 3.41M 303.63M
Deferred long term liab - - - - -
Other current liab 4.20M 3.90M 1.53M 0.34M -
Common stock 0.00026M 0.00068M 0.00231M 0.00229M 60.06M
Capital stock 0.00026M 0.00068M 7.48M 0.41M -
Retained earnings -25.46710M -25.34685M -14.51730M -2.53046M 94.58M
Other liab - - 50.72M 76.42M 8.02M
Good will - - - - 26.82M
Other assets - - 48.30M -73.51091M 2451.36M
Cash 11.99M 5.25M 1.27M 4.49M 147.12M
Cash and equivalents - - - - -
Total current liabilities 5.56M 4.45M 2.14M 1.21M 2346.97M
Current deferred revenue - - - - -
Net debt -11.99170M -5.25298M -1.25798M -4.49240M -
Short term debt - - 0.02M - -
Short long term debt - - - - -
Short long term debt total - - 0.02M - -
Other stockholder equity 32.11M 26.40M 6.93M 5.54M 1.08M
Property plant equipment - - 0.13M - 21.22M
Total current assets 12.08M 5.41M 1.91M 4.62M 154.78M
Long term investments - - - - 194.09M
Net tangible assets - - -7.82265M 3.01M 273.90M
Short term investments - - - 0.53M 185.66M
Net receivables - - - - 7.67M
Long term debt - - - - 174.18M
Inventory - - - - -
Accounts payable 1.36M 0.55M 0.60M 0.87M 1.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.07M - 48.17M 73.51M -
Deferred long term asset charges - - - - -
Non current assets total 0.14M 0.09M 0.13M 73.51M -
Capital lease obligations - 0.00000M 0.02M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00000M -0.13196M - -368.60200M -294.85200M
Change to liabilities - 2.29M 1.30M 0.00000M 0.00000M
Total cashflows from investing activities - 25.74M -0.13196M - -294.85200M
Net borrowings - 0.75M 0.01M - -14.35000M
Total cash from financing activities 15.20M 8.00M 0.03M 338.19M 327.97M
Change to operating activities - 0.13M 0.32M - -0.39100M
Net income -10.82955M -11.98684M -0.13641M 31.70M 27.63M
Change in cash 3.98M -3.21767M -74.23175M 10.67M 65.70M
Begin period cash flow 1.27M 4.49M 74.24M - -
End period cash flow 5.25M 1.27M 0.01M 74.24M -
Total cash from operating activities -11.21940M -11.09057M -0.21871M 41.09M 32.58M
Issuance of capital stock 11.72M 8.00M - - -
Depreciation 0.03M 0.02M 0.02M 1.75M 1.49M
Other cashflows from investing activities - 25.74M -74.03633M - 1.47M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - -0.81400M -0.98600M
Sale purchase of stock - - - - -
Other cashflows from financing activities 6.78M 7.40M -0.02500M - 293.89M
Change to netincome - -1.01652M 0.04M - 4.73M
Capital expenditures 0.00000M 0.13M 0.13M 0.53M 0.86M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.73097M 0.36M 0.03M - -
Stock based compensation 0.30M 0.47M - - -
Other non cash items 0.01M 0.05M -0.11244M - -
Free cash flow -11.21940M -11.22254M -0.21871M - -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
REVB
Revelation Biosciences Inc		 0.06 4.69% 1.34 - 7.79 2.88 0.51 -1.1146
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Revelation Biosciences Inc

4660 La Jolla Village Drive, San Diego, CA, United States, 92122

Key Executives

Name Title Year Born
Mr. James M. Rolke CEO & Director 1969
Mr. Chester Stanley Zygmont III Chief Financial Officer 1980
Ms. Sandra Vedrick VP of HR & Investor Relations NA
Ms. Carol Odle Sr. Director of Clinical Projects NA
Mr. Chester Stanley Zygmont III CFO & Corporate Secretary 1980
Ms. Sandra Vedrick Vice President of Human Resources & Investor Relations NA
Ms. Carol Odle Senior Director of Clinical Projects NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.